Play nice please or not fun for us investors.There's room for...

Play nice please or not fun for us investors.

There's room for both, in fact looks like we need both:

https://www.cancer.gov/news-events/cancer-currents-blog/2020/leukemia-fto-inhibitor-bisantrene-brequinar

Dr. Chen and his team are continuing to study bisantrene and brequinar as potential cancer treatments. They are currently tweaking the structure of the drugs to boost their cancer-killing effects and improve certain chemical properties—specifically the drugs’ pharmacokinetics. They are also thinking ahead to treating patients. “A single [drug] may not be sufficient to kill many types of cancer,” Dr. Chen said. “We are also testing the combination of FTO inhibitors with other therapeutic agents, including chemotherapy, targeted therapy, and immunotherapy” in lab studies, he said.The team is hopeful that they may be able to launch a clinical trial soon. The study would focus on patients with high levels of FTO in their cancer, Dr. Chen said. Drugs like bisantrene and brequinar, which target proteins that add or remove RNA chemical tags “could lead to new, promising, and unexpected therapeutic strategies for [cancer] in the near future,” Dr. Klauzinska said. Many such drugs are currently being studied, she added.